Vir Biotechnology Inc (NASDAQ:VIR) has a beta value of 1.18 and has seen 1.14 million shares traded in the last trading session. The company, currently valued at $732.66M, closed the last trade at $5.3 per share which meant it lost -$0.2 on the day or -3.64% during that session. The VIR stock price is -172.64% off its 52-week high price of $14.45 and 18.49% above the 52-week low of $4.32. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.25 million shares traded. The 3-month trading volume is 1.28 million shares.
The consensus among analysts is that Vir Biotechnology Inc (VIR) is Buy stock at the moment, with a recommendation rating of 1.44. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 10 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.74.
Vir Biotechnology Inc (NASDAQ:VIR) trade information
Over the past 30 days, the shares of Vir Biotechnology Inc (NASDAQ:VIR) have changed 1.53%. Short interest in the company has seen 11.37 million shares shorted with days to cover at 7.84.
Wall Street analysts have a consensus price target for the stock at $12, which means that the shares’ value could jump 55.83% from current levels. The projected low price target is $12.0 while the price target rests at a high of $12.0. In that case, then, we find that the current price level is -126.42% off the targeted high while a plunge would see the stock gain -126.42% from current levels.
Vir Biotechnology Inc (VIR) estimates and forecasts
The company’s shares have lost -56.20% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -77.21%.
6 analysts offering their estimates for the company have set an average revenue estimate of 2.38M for the current quarter. 6 have an estimated revenue figure of 2.38M for the next ending quarter. Year-ago sales stood 3.08M and 2.38M respectively for this quarter and the next, and analysts expect sales will shrink by -22.48% for the current quarter and -77.21% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -18.74% over the past 5 years. Earnings growth for 2025 is a modest 18.32% while over the next 5 years, the company’s earnings are expected to increase by 11.85%.
VIR Dividends
Vir Biotechnology Inc is expected to release its next earnings report on 2025-May-07 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Vir Biotechnology Inc (NASDAQ:VIR)’s Major holders
Insiders own 10.59% of the company shares, while shares held by institutions stand at 79.05% with a share float percentage of 88.41%. Investors are also buoyed by the number of investors in a company, with Vir Biotechnology Inc having a total of 329.0 institutions that hold shares in the company. The top two institutional holders are SB INVESTMENT ADVISERS (UK) LTD with over 16.68 million shares worth more than $148.49 million. As of 2024-06-30, SB INVESTMENT ADVISERS (UK) LTD held 12.2466% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 16.43 million shares as of 2024-06-30. The firm’s total holdings are worth over $146.26 million and represent 12.0632% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of May 31, 2025 , the former fund manager holds about 3.99% shares in the company for having 5.52 shares of worth $29.27 million while later fund manager owns 3.44 shares of worth $18.23 million as of Mar 31, 2025 , which makes it owner of about 2.49% of company’s outstanding stock.
